Biotech entity
Each story carries 2 original sources on average, compared with 4.3 for the broader beat in this window. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Moderna Inc. is most often covered alongside AlphaCore Wealth Advisory, which appears in 1 of these 3 stories.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Each story carries 2 original sources on average, compared with 4.3 for the broader beat in this window. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Moderna Inc. is most often covered alongside AlphaCore Wealth Advisory, which appears in 1 of these 3 stories. That works out to roughly 0.2 stories per week across a 128-day span. At 6.3, the average consequence score sits below the same-window beat average of 6.4. We currently track 3 Biotech stories that mention Moderna Inc., published between March 16, 2026 and July 21, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 287 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moderna Inc.. Shared-story counts are live from our verified record — not editorial picks.
Cramer Endorsement & 109% YTD Gain
Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
Chip Tumble and Moderna Rally
PHLX chip index dropped 5.3% on AI profitability concerns. Apple rebounded 3.1%. Moderna hosted an investor event, sending its stock up nearly 13%. S&P 500 closed marginally lower.
Inflation Data Released and Apple Price Hike
May US inflation data showed a rise above 4%, fueled by energy costs from the Iran war. Apple raised prices on iPads and MacBooks, citing memory chip costs, leading to a sell-off in its shares.
Quarterly Update
Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
Market Impact
Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
Refusal to File
Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
Grants Rescinded
The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
Workaround Supported
FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
Collaboration Begins
Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.
Post-Pandemic Decline
Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
COVID Vaccine Success
Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.
Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Source: Adria Cimino (us) · fool.com
Moderna's investor event sent its shares soaring nearly 13%, marking a pivotal day for the biotech industry. The rally highlights how pipeline disclosures can dramatically move markets and reaffirm investor appetite for innovation.
Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Moderna Inc. is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
